ARTELO BIOSCIENCES, INC. Unamortized Debt Issuance Expense
ARTELO BIOSCIENCES, INC. (ARTL) had Unamortized Debt Issuance Expense of $2.36 million as of 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2022-11-08
- 2022-09-30: Unamortized Debt Issuance Expense $2.36M.
- 2022-06-30: Unamortized Debt Issuance Expense $3.00K.
- 2022-03-31: Unamortized Debt Issuance Expense $3.56M.
- 2021-11-30: Unamortized Debt Issuance Expense $3.68M.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2022-09-30 | $2.36M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $3.56M 10-Q · filed 2022-05-12 |
| 2021-11-30 | $3.68M 10-Q · filed 2022-01-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |